Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day. Repeatedly, the company has announced positive data from its gene editing trials, only to watch the stock slide.

The stock market is notoriously fickle, particularly around buzzy gene-editing companies. Yet the selloffs pointed to real questions around the biotech’s programs: Clearly, its CRISPR-based drugs were effective. But were they any more effective than other drugs that use older, less sci-fi technologies?

Intellia tried to allay some of those concerns on Saturday with new year-long data from the 36 patients treated in an early trial of its CRISPR drug for ATTR cardiomyopathy.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Concert-goers sync up physically and emotionally in fascinating study

Researchers examined physiological and motor synchronization in audiences during live classical concerts and explored their correlation with aesthetic experiences and individual personality traits.

October 5, 2023

Federal court gives Teva and Viatris another chance to invalidate J&J’s last patent for Invega Sustenna

Johnson & Johnson only has one last patent covering its long-acting blockbuster schizophrenia drug Invega Sustenna, and now Teva and Viatris have another opportunity to

April 3, 2024

Only Certain Groups of People Should Take Very High Vitamin D Doses

BOSTON — Most healthy adults under 75 can get by with the recommended daily allowance of vitamin D, but some groups should supplement with more,

June 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.